EMA issues 2026 veterinary PV recommendations as human-side label actions pile up

What happened

On 9 November 2026 the European Medicines Agency published a document setting out pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2026. It sits in the agency's regulatory and procedural guideline section. The file name points to the CVMP, the committee that handles veterinary medicines, and to product information updates.

The records available to us do not describe the document's contents. We cannot say which products, active substances or safety topics it covers, how many products are affected, or whether any recommendation changes existing practice. Anyone working on a centrally authorised veterinary product should read the PDF directly rather than rely on summaries, including this one.

Why a veterinary document matters to PV teams

Veterinary pharmacovigilance gets far less attention than human PV, and many human-medicine QPPVs never touch it. The mechanics are familiar, though. Safety data is collected, signals are assessed by an EU committee, and the outcome is a recommendation that ends up in the summary of product characteristics and other product information. A document framed around 2026 recommendations for centrally authorised products suggests this loop is being tracked at the level of the whole portfolio, not just product by product.

For companies holding both human and veterinary authorisations, or sharing active substances across the two, it is worth checking whether anything in the document touches their portfolio. Whether it does is not yet known from the material we have.

The same pipeline, visible elsewhere this week

Other items published the same day show the same pipeline at work on the human side, in different forms.

FDA is requiring application holders for every GLP-1 receptor agonist to add a Warnings and Precautions entry on a potential increased risk of NAION, a rare optic nerve condition. This is a class-wide labelling action, and it applies to every holder, not only the originators.

FDA's CBER says postmarketing reports for Zolgensma include tumours with vector integration near the GLI1 oncogene. It is weighing regulatory action on Zolgensma and Itvisma. No decision has been announced, and the outcome is not yet known.

On the EU side, EMA has published Revision 1 of its draft guideline on assessing risks in human reproduction and breastfeeding, covering the path from data to product information. It is a draft, so it will not bind anyone until it is finalised, but it shows how the agency expects evidence to be turned into label wording.

Taken together, these show that product information is the main output of pharmacovigilance. Whether the subject is a veterinary product, a GLP-1 or a gene therapy, the question is how evidence gets into the label and how fast.

Quality and device signals sit alongside

Several other items from the same day are quality-driven rather than label-driven, and they are a reminder of how broad PV work is. FDA classified the Abiomed Automated Impella Controller removal as Class I, citing quality issues that could delay therapy or cause loss of haemodynamic support. It also upgraded its Early Alert on Cardinal Health Presource convenience kits containing BD Alaris Pump infusion sets to Class I. Eugia US is recalling one lot of vancomycin for injection to hospital level after a glass particle was found in a vial; no adverse events have been reported.

Class I is FDA's most serious recall category. These cases show that complaint handling, quality defect reporting and safety surveillance feed the same decisions. Pharmacovigilance teams that treat product quality events as someone else's problem risk missing the earliest indication of patient harm.

What to watch

First, the contents of the veterinary document. Teams should check for product-specific recommendations and any timelines tied to them. Second, whether FDA's investigation of Zolgensma and Itvisma leads to labelling or other regulatory action, and whether EU authorities respond; nothing in our records indicates that yet. Third, the consultation path and eventual finalisation of the reproduction and breastfeeding guideline, which will shape how teams justify label language on pregnancy and lactation. Finally, whether the GLP-1 NAION wording is mirrored by other regulators, which is not yet known.